Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 5/20 | 0.48 |
| ▸ | CDK4 | P11802 | 12/20 | 0.47 |
| ▸ | CCND1 | P24385 | 10/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 8/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 8/20 | 0.47 |
| ▸ | FGFR4 | P22455 | 8/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 8/20 | 0.47 |
| ▸ | CDK2 | P24941 | 8/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.47 |
| ▸ | SYK | P43405 | 2/20 | 0.47 |
| ▸ | CCND3 | P30281 | 5/20 | 0.44 |
| ▸ | CCND2 | P30279 | 3/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.44 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19010244 | 0.99 | FLT3 (0.49) | FLT3CDK4CCND1FGFR1FGFR2 | |
| SCHEMBL17009132 | 0.90 | SYK (0.53) | FLT3CDK4CCND1FGFR1FGFR2 | |
| SCHEMBL17021335 | 0.89 | SYK (0.54) | FLT3CDK4CCND1FGFR1FGFR2 | |
| SCHEMBL19010248 | 0.89 | SYK (0.51) | CDK4CCND1CDK2SYKCCND3 | |
| SCHEMBL19010271 | 0.88 | SYK (0.52) | CDK4CCND1CDK2SYKCCND3 | |
| SCHEMBL19010247 | 0.86 | SYK (0.48) | CDK4CCND1SYKCDK6 | |
| SCHEMBL19010246 | 0.84 | CDK4 (0.43) | CDK4CCND1FGFR1FGFR2FGFR4 | |
| SCHEMBL19010284 | 0.84 | CDK4 (0.44) | FLT3CDK4CCND1FGFR1FGFR2 | |
| SCHEMBL17009111 | 0.82 | SYK (0.56) | CDK4CCND1SYKCCND3CCND2 | |
| SCHEMBL17021331 | 0.81 | SYK (0.57) | CDK4CCND1SYKCCND3CCND2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834548-B2 | Pyridazine compounds as JAK inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | JAK1, JAK2, JAK3 | FLT3 102/4885CDK4 163/4885CCND1 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.